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ABSTRACT 
 
Survival rates for Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma have 
improved in recent years.  However, these improvements are associated with various 
late effects, which can compromise health-related quality of life (HRQoL).  
Improving HRQoL is a significant goal in oncology, and increasingly one of the 
primary outcomes in clinical trials, but is dependent on availability of reliable and 
sensitive measures. This review therefore aimed to: (i) identify and evaluate 
commonly used HRQoL measures; (ii) compare HRQoL in lymphoma patients with 
the general population; and assess the  association between (iii) HRQoL and different 
treatments; and (iv) HRQoL and demographic, medical and psychological variables.  
Standardized systematic searches identified 18 eligible studies that included adult 
survivors of lymphoma and reported quantitative results by histological diagnosis. 
Information about design, sample, measures and findings was extracted from each 
study. Survivors of lymphoma experienced worse physical but comparable mental 
HRQoL to the general population.  No conclusions could be drawn about the 
association between different treatments and HRQoL.  Correlates of better HRQoL 
included younger age, educational level, being employed, male gender, earlier stage 
disease, not having co-morbid illnesses, and meeting public health exercise 
guidelines.  Limitations of current research relating to research design, sample 
demographics and reporting of descriptive statistics were identified.  Given the 
increasing numbers of patients living with lymphoma, controlled studies using 
appropriate measures are required to determine the HRQoL consequences associated 
with the condition. 
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The lymphomas [Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s Lymphoma 
(NHL)] are among the most common cancers to affect individuals of all ages although 
NHL tends to be more common in older people [1].  Survival rates for both cancers 
have improved rapidly, and current five-year survival rates of 87% for HL [2] and 
65% for NHL [3] have been reported.  However, physical late effects, including 
cardiac dysfunction, secondary malignancies, neuro-cognitive impairment and 
gonadal dysfunction have been identified [4].  Such effects may compromise health-
related quality of life (HRQoL). This is typically defined as a multidimensional 
concept covering all aspects of well-being, including physical functioning (ability to 
carry out everyday physical activities), mental functioning (emotional functioning), 
social functioning (ability to interact in the usual way in society) and role functioning 
(involvement in life situations related to work, household chores, and family life) [5].  
Improving HRQoL is a significant goal in oncology, and increasingly one of the 
primary outcomes in clinical trials [6].  
 
 HRQoL has been assessed in survivors of HL and NHL in a number of 
studies, but the evidence has not been reviewed systematically.  Such a review would 
facilitate understanding of long-term HRQoL among lymphoma survivors and the 
extent to which it may be influenced by medical, demographic and psychosocial 
factors.  This information could in turn enable healthcare professionals to provide 
patients with information about the long-term impact of their disease, suggest ways in 
which late effects may be prevented or reduced, and provide an indication about who 
would benefit from counselling. 
 
 Any conclusions about HRQoL are necessarily dependent on the quality of 
measures available.   Measures can be evaluated on a number of criteria including: 
reliability (test-retest reliability and internal consistency), validity, and 
appropriateness for the population of interest [7]. Reliability is usually indicated by 
internal consistency or Cronbach’s alpha, the extent to which the items of a scale 
assess the same concept.  An internal consistency of 0.70 or above is generally 
considered to be acceptable [8]. Test-retest reliability is established when individuals 
complete a measure on two separate occasions and their scores are highly correlated.  
Page 3 of 25
URL: http://mc.manuscriptcentral.com/glal
Leukemia and Lymphoma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
4 
Validity refers to the extent to which the measure reflects the construct of interest.  It 
is generally assessed by comparison with similar measures and correlation with 
observable criteria.  Finally, for this review, measures were considered appropriate for 
lymphoma survivors if they were either generic (applicable to anyone) or survivor-
specific.  Measures designed to assess HRQoL during initial treatment, with their 
emphasis on physical symptoms were not considered sensitive to the issues affecting 
survivors..  
 
We therefore report a systematic review to determine HRQoL in survivors of 
HL or NHL. Our first aim was to identify and evaluate commonly used measures. In 
addition, we aimed t  determine (i) HRQoL relative to the general population; (ii) 
associations between HRQoL and different treatments; and (iv) associations between 
HRQoL and demographic, medical and psychological variables.  
 
METHOD 
The literature search aimed to identify any research study published in a peer 
reviewed journal that assessed HRQoL in survivors of lymphoma (HL or NHL) at 
least six months post treatment, using a standardized measure of HRQoL.   Articles 
were excluded if they: (i) sampled childhood cancer survivors only; (ii) were case 
reports or reviews of previous literature; or (iii) did not report analyses by histological 
diagnosis. 
 
Three methods were used to locate relevant studies: a keyword search, a 
backward search, and a manual search of relevant journals.  First, the databases 
Medline, PsycInfo and Web of Knowledge were searched for articles published in the 
English language covering the period from January 1985 to April 2009.  The search 
included the following terms: Hodgkin’s disease, lymphoma (non-Hodgkins), and 
health-related quality of life.  After each term was entered into the keyword function 
the cancer-related terms were combined using the OR function.  This generated 32 
hits from PsycInfo, 157 hits from Medline, and 456 hits from Web of Knowledge. 
After initial review of the abstracts those that did not meet the inclusion criteria were 
excluded.  This resulted in identification of 36 articles as potentially eligible. Despite 
extensive searches, one article [9] could not be traced.  Following the keyword search, 
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we then carried out a backward search in which we located papers by examining the 
reference lists of all papers obtained from the first step.  This identified nine further 
articles.  Then, following a manual search of the journals ‘Psycho-Oncology,’ 
‘European Journal of Cancer,’ ‘Journal of Clinical Oncology’ and ‘Quality of Life 
Research’ for the period January 1985 to April 2009, one further article was 
identified.  This resulted in a total of 45 articles that were obtained and examined 
against the inclusion and exclusion criteria. 
 
RESULTS 
Review of the articles 
Following detailed review of the articles against the inclusion/exclusion criteria, 18 
articles based on 15 data sets were retained. The following information was extracted 
from each study: aims, sample size by histological diagnosis (including percentage of 
men) and response rate, age, time since diagnosis, treatment, comparison group where 
applicable, measures and results.  The studies were conducted in the US (n=4), 
Norway (n=3), the Netherlands (n=2), Israel, France, Spain, Sweden, Austria and 
Canada (1 each).  All studies included demographic or medical variables as correlates 
of HRQoL.   
 
Aim 1: Evaluation of Measures 
Five different measures of HRQoL were identified.  These are summarized 
and assessed for reliability, validity and appropriateness for lymphoma survivors in 
Table I. We identified eight studies which utilised a generic measure (the SF-36 
health survey; [10]) to compare lymphoma survivors to the general population.    The 
remaining measures were disease specific.  These included three appropriate for 
assessment during treatment (EORTC QLQ-C30: [11]; FACT-An: [12]; CARES 
[Ganz et al., 1992][13]) and one designed for survivors (QoL-CS: [14] – two studies).   
 
 
Aim 2: HRQoL relative to the general population 
 HRQoL was compared with that of the general population in ten articles that 
covered eight datasets. These articles are summarised in Table II.  Eight articles 
covering six datasets [15, 17, 19-24] made these comparisons using the SF-36 health 
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survey [10].  In all eight articles, lymphoma survivors reported worse physical 
functioning relative to the general population even when controlling for symptoms of 
post-traumatic stress disorder (PTSD) [15].  Lymphoma survivors also reported worse 
social functioning relative to the general population [19].   However, the mental 
component summary (which in the SF-36 includes emotional and social but not 
cognitive function) did not differ significantly from the general population in any of 
these eight studies, although impaired functioning relative to controls was noted on 
some subscales [19, 20].  The mental component summary is more reliable and 
comprehensive than the subscales it comprises.  
 
Two additional articles [16, 18] compared lymphoma survivors with the 
general population using the EORTC QLQ-C30 (see Table II).  Lymphoma survivors 
reported worse physical functioning than the general population in both studies.  In 
addition, survivors reported worse social functioning, more fatigue, more problems 
with physical role and cognitive functioning [18], and more dyspnoea (shortness of 
breath) [16, 18].    
Aim 3:  Associations between treatments and HRQoL 
Details about associations between treatments and HRQoL are reported in 
Tables II and III.  Lymphoma survivors who had been treated by chemotherapy 
reported worse social well-being (as measured by the CS-QoL) and worse 
psychological well-being relative to survivors who had not had chemotherapy [22].  
They also reported worse social and physical well-being, more fertility concerns, and 
greater influence of cancer and its treatment on employment relative to those who had 
had radiotherapy specific to the tumour site [25].  Those who had experienced mantle 
field radiation either alone or in combination with chemotherapy had more dyspnoea 
than those who had not [30].  Finally, survivors who had experienced combined 
modality therapy (chemotherapy plus radiotherapy) reported more deficits in physical 
functioning, dyspnoea, pain and fatigue than those who had been treated by either 
chemotherapy or radiotherapy alone [29].   
 
However, the evidence above is based on studies with heterogeneous samples 
which precluded comparisons between chemotherapy regimens.  A cross-sectional 
comparison of MOPP, ABVD and MOPP/ABVD chemotherapy demonstrated no 
differences in terms of effects on physical and mental HRQoL [16].  Finally, a 
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randomised controlled trial in which patients were followed for two years [28] 
demonstrated no differences between subtotal lymphoid irradiation alone versus 
combined with doxorubicin and vinblastine chemotherapy in terms of effects on 
physical and psychosocial HRQoL.  
 
Aim 4: Associations between HRQoL and and demographic, medical and 
psychological variables 
 
Demographics 
 Although older age was associated with worse physical HRQoL [16, 18-19, 
22, 32], worse mental functioning was found for younger patients [29].  Men reported 
better role functioning [18], fewer role limitations [19] better physical functioning 
[16, 19] and better emotional functioning [19] than women.    In contrast, one study 
found that men experienced greater fatigue and worse overall HRQoL than women 
[30].  Lower educational level was associated with worse HRQoL [18-19, 21].  
Finally, employed survivors reported better physical functioning than unemployed 
survivors [21, 32], as well as better emotional HRQoL and general health [21] and 
better vitality and mental functioning [22].   
Medical variables 
More advanced disease was associated with worse HRQoL [24], but those 
who relapsed did not report worse HRQoL than those who remained disease-free [23]. 
Better vitality, social functioning, emotional role and mental health were found for 
those 10-15 years post-diagnosis than those 5-9 years post-diagnosis [20, 22].  In 
contrast, Greil et al. [29], found no relation between time since treatment and any 
domains of HRQoL.  The presence of co-morbid illnesses was associated with worse 
physical HRQoL [18, 21-22, 32]. 
 
Psychosocial, lifestyle and other variables 
More PTSD symptoms were associated with worse mental and physical 
functioning [15].  A lower sense of coherence (defined as the extent to which 
individuals believe their life to be comprehensible, meaningful and manageable) [33] 
was associated with worse HRQoL [24].  Financial problems were associated with 
worse mental functioning [24, 26].  Meeting public health guidelines for exercise was 
associated with better HRQoL in patients with NHL [27, 31]. This was a significant 
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dose-response relation, where HRQoL improved as exercise increased [27].   Patients 
experienced more dyspnoea if they were older, had a lower educational level and a 
history of medical complications [18].  Finally, sleep disturbance was associated with 
dyspnoea, fatigue, pain, financial difficulties and worse global HRQoL [30]. 
 
DISCUSSION 
In considering the HRQoL of survivors of lymphoma, we recognise first the 
importance of the specific measure of HRQoL adopted. All measures identified had 
acceptable reliability and validity (table 1). Three of the measures identified (the 
EORTC QLQ C-30 [11], the FACT [12] and the CARES [13] might be considered 
inappropriate for cancer survivors since they capture immediate effects of diagnosis 
and treatment rather than issues relating to re-integration and late effects [34].   
Further, as a cancer-specific measure, the EORTC measure is inappropriate for use by 
general population controls.  Despite this, two studies compared HRQoL between 
lymphoma patients and the general population using this measure.  Thus, the 
conclusions should be treated with caution.   
 
Most frequently, HRQoL was assessed using the SF-36 [10]. This is a generic 
measure, and therefore appropriate for comparison with the general population but 
does not address the specific problems experienced by cancer survivors. The only 
measure specifically developed for cancer survivors is the QoL-CS [14].  However, 
several issues have been identified with this measure: although it is intended for 
survivors longer than five years post diagnosis, validation was based on survivors 4-
28 months post-diagnosis; several items assess distress at the time of diagnosis and 
treatment; and some items ask about change but fail to indicate direction (meaning 
that survivors with positive and negative responses would receive the same scores) 
[35].  Further, there are no disease-specific modules for survivors, even though some 
late effects differ as a function of cancer site. 
 
 In an attempt to address these issues, it has been recommended that studies 
should use two measures where possible: a survivor-specific measure to assess quality 
of life, and a generic measure [36-37]).  Attention needs to be given to creating more 
sensitive measures of quality of life for cancer survivors, so that their problems can be 
documented and addressed appropriately (see also [38]). 
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With these comments in mind, the evidence suggests that on average long-
term survivors of lymphoma experience good overall mental HRQoL relative to the 
general population, although some medical and demographic variables constitute risk 
factors.  Where there are concerns that mental HRQoL is severely compromised, it is 
important to supplement HRQoL measures with more established measures of 
emotional functioning or psychiatric assessment. In contrast, long-term survivors of 
lymphoma report poorer physical HRQoL relative to matched controls, suggesting 
that diagnosis and treatment impact more on physical than mental health in the long 
term.  Although poorer physical HRQoL relative to the general population might be 
expected given the incidence of late medical complications and fatigue in lymphoma 
survivors [39], it is also possible that current measures provide more sensitive 
assessment of physical than mental HRQoL.  
 
There is some evidence that HRQoL in the first two years after diagnosis does 
not differ depending on the specific treatment [28].  However, the participants in this 
study were younger than the general population with lymphoma.  Since many late 
effects are not apparent until several years after treatment, more long-term follow up 
studies are required to compare the relative side-effects of different treatment 
regimens.   We found some evidence that chemotherapy is associated with worse 
social HRQoL relative to other treatments [22, 25].  Chemotherapy often leads to 
fatigue [40], which may account for this finding.  However, patients with advanced 
stage disease are also more likely to be treated with chemotherapy, meaning that the 
effect of treatment may be confounded by stage [25].     
 
The relation between older age and worse physical HRQoL was expected, and 
can be explained in several ways.  First, older people are more likely to suffer from 
co-morbid illnesses.  Second, some late effects are more likely to occur as time since 
treatment (and therefore age) increases [4]. Furthermore, physical health tends to 
decline with age for the general population. 
 
Lower educational level was associated with worse HRQoL in three studies. 
Lower socioeconomic status has been associated with a less healthy lifestyle in 
general [41] which may be reflected in poorer HRQoL, probably because those with 
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lower educational qualifications are also likely to be lower earners.  Such patients are 
more likely to be employed in manual work, and consequently may have to take more 
time off work following completion of treatment, leading to constraints in their 
financial circumstances, which have been associated with worse mental health [25].  
In support of this idea, unemployment was associated with worse physical HRQoL 
[21].   
 
Survivors who reported meeting public health exercise guidelines (150 
minutes of moderate intensity activity per week) also reported better HRQoL [27, 31].  
This relation held after controlling for age, gender, employment status, time since 
diagnosis and co-morbid conditions.  Although patients in better health may be able to 
exercise more, this evidence suggests that advice to take as much exercise as is 
feasible is potentially valuable.   
 
The relation between psychological variables and HRQoL was assessed in 
only two studies [15, 24].  Associations between psychological variables and HRQoL 
might suggest ways to improve guidelines for appropriate referral to psychological 
services.  Appropriate treatment for psychological issues would be likely to facilitate 
survivors’ attainment of the best HRQoL possible.  However, in order to facilitate 
this, psychological issues should be assessed at follow-up.  This is particularly 
important as psychological late effects of treatment are often not documented in 
medical notes [42] and thus may not be addressed by clinicians. 
 
A number of limitations with current methodology can be identified.   Only 
nine of the studies utilised research designs which were longitudinal or case-control.  
Longitudinal studies are essential to understand changes in HRQoL over time.  Case-
control studies facilitate judgement about whether HRQoL is really compromised 
relative to age-matched controls from the general population, and may provide greater 
accuracy than population norms.  
 
More detailed description is required regarding sample demographics.  First, 
results were not analysed by gender although three studies [18-19, 30] suggested 
gender differences in HRQoL.  Identification of gender differences may aid clinicians 
in deciding what aspects of HRQoL to assess in patients, and facilitate identification 
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of correlates of HRQoL.  Second, as a minimum, information is needed on 
socioeconomic status (assessed by more than one method where possible) and marital 
status.  Third, studies should differentiate between survivors younger than 45 and 
older patients, as younger patients may have qualitatively different concerns [43].   
 
More detailed reporting of descriptive statistics is also required.  Many studies 
failed to report means and standard deviations.  These enable comparison between 
studies, and are necessary for calculating effect sizes in meta-analysis [44].  
Particularly where research is based on small samples from specific treatment centres, 
meta-analyses may be the only way to obtain information based on larger samples, 
and thus identify common trends across regions and cultures.  They also enable 
assessment of individual predictors of HRQoL such as personality or demographic 
factors. 
 
 Serious attention should be paid to creating well-designed studies that include 
matched controls, and using measures that assess the full range of problems 
experienced by lymphoma survivors, including disease-specific modules where 
possible.  Also, analyses should be carried out by gender in order to further 
understanding of demographic, medical and psychosocial correlates of HRQoL in 
survivors of lymphoma. This would enable clinicians to provide patients with better 
advice about the late effects of their disease, and suggest ways in which these effects 
may be prevented or mitigated.   
 
Due to the methodological issues underlying research into HRQoL following 
lymphoma, only limited conclusions can be drawn.  However, this review has clearly 
identified pathways and recommended standards for future research.  In conclusion, 
we note the progress made in treatment of lymphomas, as demonstrated in the 
increasing numbers of survivors.  Comparable progress is now needed to determine 
the range, severity and prevalence of untoward consequences of lymphoma and its 
treatment, and how to mitigate those consequences.   
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Table I: Description of measures used 
Scale Subscales Reliability Validity Type of 
measure 
SF-36 [8] 
(Ware et al., 
2002) 
Physical component summary (physical functioning, 
role limitations due to physical problems, bodily pain, 
general health) 
Mental component summary (social functioning, role 
limitations due to emotional problems, vitality, mental 
health) 
Test-retest; 
α > 0.70 
Correlates with observable physical 
outcomes 
Generic 
EORTC QLQ-
C30 [9] 
(Aaronson et 
al., 1993) 
Physical, Role, Emotional, Cognitive and Social 
functioning, Global health status, Physical symptoms 
(fatigue, nausea and vomiting, pain, dyspnoea, sleep 
disturbance, appetite loss, constipation, diarrhoea) 
Test-retest; 
α > 0.70 
Distinguishes patients with different 
performance status 
Cancer-
specific; 
appropriate  
during 
treatment 
FACT-An [10] 
(Cella et al., 
1997) 
Physical, Functional, Emotional, Social well-being, 
Anaemia symptoms 
Test-retest; 
α > 0.70 
Discriminates based on medical 
variables; correlated with appropriate 
scales 
Cancer-
specific; 
appropriate
during 
treatment 
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CARES (Ganz 
et al., 1992) 
Physical, psychosocial, marital, medical interaction, 
sexual 
Test-retest; 
α > 0.70 
Comprehensive; correlates with 
appropriate scales 
Cancer-
specific; 
appropriate 
during 
treatment 
QoL-CS [11] 
(Ferrell et al., 
1995) 
Physical, Psychological, Social, Spiritual well-being Test-retest; 
α > 0.70 
Correlates with appropriate scales, 
discriminates based on demographic 
and medical variables 
Cancer-
specific: 
survivors 
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Table II: Correlates of quality of life: studies with comparison group 
Study and 
country of origin 
Aims Sample 
(response 
rate) 
Age 
(Mean, 
(range) 
[SD]  
Time since 
diagnosis 
(Mean, 
range) 
(years) 
Treatment (n) Comparison 
Group (n) 
Measures Findings 
1. Geffen et al. 
(2003) [12] 
Israel 
 
1. Assess frequency of 
PTSD and PTSD 
symptoms relative to 
controls 
2. Explore relation 
between PTSD and 
HRQoL 
 
44 (96%):  
36 HL,  
8 NHL 
(46% men) 
51 (27-80) 7.9 (2-16) all 
2 yrs + since 
treatment 
RT: 6 
CT: 24 
Both: 14 
44 matched 
controls (sex, 
marital status, 
education, age) 
experienced 
traumatic event 
SF-36 1) Lower physical HRQoL than 
controls, even after controlling for 
PTSD symptoms  
2) Higher intensity PTSD a/w lower 
HRQoL 
 
2. Gil-Fernandez 
et al. (2003) [13] 
Spain 
1. Assess HRQoL and 
psychological well-being 
of Spanish survivors 
46 (68.6%) 
32 men 
43 (15-80) 7.6 (0.8-
22.1) 
RT: 7 
CT: 10 
Both: 29 
46 GP, matched 
for age, sex, 
social status 
EORTC 
QLQ-C30 
1) Worse physical function, family 
relationships, more dyspnoea and 
economic difficulties than general 
population 
2) Women worse physical HRQoL 
than men 
 
3. Hjermstad et 
al. (2006) [14] 
Norway 
1. Assess HRQoL in 
survivors with chronic 
fatigue 
475 HL 
(80%) 
56% men 
46 (21-74) 195 (53-431) 
months 
RT/CT GP (2141), 
same age range 
as patients, 
adjusted for sex, 
educational 
level 
 
SF-36 1) Lower physical HRQoL than 
general population, chronic fatigue 
3x higher  
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4. Joly et al. 
(1996)  [15] 
France 
1. Determine type and 
frequency of 
psychosocial problems in 
French long-term 
survivors relative to 
controls  
93 HL 
(91%) 
Numbers of 
each gender 
not reported 
separately 
for patients 
and controls 
42 (23-85) 10 (4-17) RT: 34% 
CT: 4% 
Both: 62% 
MOPP: 74% 
ABVD: 16% 
Both: 10% 
186 GP, 
matched for age, 
sex, city of 
residence 
EORTC 
QLQ-C30 
1) Lower physical, role cognitive 
and social functioning, more 
dyspnoea, fatigue than general 
population 
2) Men better role functioning than 
women 
3) Lower educational level: worse 
physical, role functioning, more 
dyspnoea 
4) Medical complications: more 
dyspnoea, lower physical, role and 
cognitive function 
 
5. Loge et al. 
(1999) [16] 
Norway 
1. Compare HRQoL with 
norms from general 
population 
2. Determine disease or 
treatment factors 
affecting HRQoL  
459 HL 
(82%) 
56% men 
44 [11.8] 12.2 (3-23) RT: 174 
CT: 66 
Both: 217 
RT: 76% 
mantle field 
LVPP: 54% 
ABOD: 46% 
As for 3 SF-36 1) )  Lower vitality, general health, 
physical functioning, role physical, 
social functioning than general 
population  
2) Men better role physical, 
physical functioning, role emotional 
than women 
3) More education: better physical 
HRQoL 
 
6. Mols et al.* 
(2006) [17] 
Netherlands 
1. Examine differences 
between survivors and 
age-matched controls  
2. Compare HRQoL of 
5-9 years and 10-15 
years survivors  
132 NHL 
(80%) 
Gender not 
reported 
20-34; 
35-49;50+  
48: 
5-9 yrs 
68: 
10-15 yrs 
 
RT: 25 
CT: 38 
Both: 66 
Age-matched GP 
(1771) 
SF-36;  
QOL-CS 
1) 5-9 yrs: lower general health, 
social functioning, mental health 
than controls  
2) 10-15yrs: lower general health 
than controls, but higher physical 
functioning  
3) 10-15 years:  higher HRQoL 
than 5-9yrs survivors: vitality, 
social functioning, role emotional, 
mental health 
 
Deleted: ¶
Page 20 of 25
URL: http://mc.manuscriptcentral.com/glal
Leukemia and Lymphoma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
For Peer Review Only
21 
 
7. Mols et al. 
(2007a) * [18] 
Netherlands 
1. Compare HRQoL with 
general population  
2. Compare survivors 
over and under 70 
155 NHL 
survivors 
(80% of full 
sample) 
54% male 
70 Not reported 
by disease 
Surgery: 22 
RT: 85 
CT: 115 
Surveillance: 
12 
Combinations 
not reported 
As 6 SF-36 1) Younger: lower vitality, general 
health, but less pain 
2) Co-morbidity: worse social 
function, physical health, role 
emotional,  
3) More education: better physical 
function 
4) Employed: better role physical, 
role emotional, general health 
 
8. Mols et al. 
(2007b)* [19] 
Netherlands 
1. Investigate association 
of demographic and 
clinical factors with 
HRQoL  
2. Compare HRQoL to 
general population 
221 NHL 
survivors 
(82%) 
51% male 
55.3 5-9 yrs: 145 
months 
10-15yrs: 76 
months 
RT: 33 
CT: 82 
Both: 58 
Also surgery: 
28 
Wait: 20 
As 6 SF-36;  
QOL-CS 
1) Chemo: lower social and 
psychological well-being  
2) Older age: lower physical 
functioning 
3) Co-morbid conditions:  poorer 
physical functioning, more pain 
4) Employed: better vitality, mental 
health 
5) Longer since diagnosis: better 
social well-being (QoL-CS) 
 
9. Van Tulder et 
al. (1994) [20] 
Netherlands 
1. Examine HRQoL, 
prevalence, severity of 
psychosocial problems in 
long-term survivors 
81 HL(92%) 
42 male 
43.6 (25-77) 14 (2.0) All: mantle 
field radiation 
CT: 19 
Vinblastine: 5 
 
MOPP: 14 
114 age-matched 
healthy hospital 
visitors 
SF-36 1) Lower physical functioning, role 
physical, general health than 
controls 
10. Wettergren et 
al. (2004) [21] 
Sweden 
1. Evaluate HRQoL in 
long-term HL survivors 
2. Identify determinants 
of HRQoL  
121 (62%) 
55% male 
47 (23-75) 13 (6-24) RT: 55 
CT:28 
Both: 17 
236 GP (stratified by 
age and sex) 
SF-12 1) Poorer physical health than 
controls  
2) More advanced disease: more 
disease-related problems 
3 Lower sense of coherence: worse 
HRQoL 
Glossary: SF-36: Short Form-36 health survey; RT – Radiotherapy; CT – chemotherapy; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire; GP – general population; QOL-CS: Quality of Life-Cancer Survivors; MOPP – Mechlorethamine, vincristine, procarbazine, prednisone; 
ABVD – Doxorubicin, bleomycin, vinblastine, dacarbazine;  LVPP – Chlorambucil, vinblastine,  procarbazine, prednisone;  ABOD – doxorubicin, bleomycin, vincristine, 
dacarbazine 
* These studies are drawn from the same population 
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Table III: Correlates of quality of life: studies without comparison group 
Study Aims Sample 
(response 
rate) 
Age 
(Mean, 
(range) [SD] 
Time since 
diagnosis 
(years) 
(Mean, 
(range) [SD] 
Treatment Measures Findings 
1. Ahles et al. 
(2005) [22] 
USA 
1. Compare QoL of long-term 
survivors of lymphoma treated with 
chemotherapy or surgery 
103 (76% 
overall) 
Chemo: 45% 
male 
Surgery: 
48.7% male 
Chemo:  
55.8 [13.5] 
Surgery:  
50.4 (12.8) 
10.0 [5.3] CT: 66 
Surgery: 37 
QOL-CS 1) Chemo: worse social and physical QoL – 
more fatigue, aches and pains, worse overall 
health 
2) Chemo: more fertility concerns, greater 
interference of cancer and treatment on 
employment  
 
2. Bellizzi et al. 
(2007)* [23] 
USA 
1. Describe association between 
demographic, disease-related and 
psychosocial factors, and positive 
and negative life change 
 
NHL 308 
(72.5%) 
51.3% male 
60 (23-85) 3.5 [0.1] CT: 94.2% SF-36 1) Increase in negative life change: decline 
in physical and mental functioning  
3. Bellizzi et al. 
(2009)* [24] 
USA 
1. Examine demographic, disease-
related and cognitive factors a/w 
physical activity in NHL survivors 
2. Explore relation between 
physical activity and HRQoL 
NHL 319 
(72.5%) 
51.3% male 
59.8 (14.8) 2-5.9 (3 
groups) 
CT: 156 
CT+ RT: 108 
Transplant: 34 
SF-36 1) Met guidelines for exercise or some 
activity: better mental and physical health 
than if sedentary, significant dose-response 
pattern 
2) Similar results - anxiety and depression 
3) 25% 1 SD below norm – mental health, 
1.5 SDs below norm – physical health 
 
4. Ganz et al. 
(2003) [25] 
USA 
1. Examine outcomes during first 
two years after assignment to STLI 
or CMT in SWOG trial 
Baseline 237 
(97%) 
60% male 
2 yrs: 160 
(70%)  
Radiation: 
31.4 (17-85) 
Combined: 
33.7 (17-71) 
Recruited at 
diagnosis, 2 
yr follow-up 
At 2yrs 
STLI: 78 
STLI+CMT: 82 
CARES-
SF; SF-36 
vitality, 
general 
health 
1) No differences between radiation and 
combination therapy at 2 years in terms of 
effects on HRQoL, vitality 
2) Physical, psychosocial, sexual, marital 
and medical interaction returned to baseline 
2) General health worse at 2 years 
 
5. Greil et al. 
(1999) [26] 
Austria 
1. Assess QoL in HD survivors  
2. Investigate impact of different 
treatment modalities on QoL 
 
HD 126 
(64.9%) 
99/225 
male (44%) 
36.9 
(6-89) at 
diagnosis 
10.5 (0.9-
34.0) 
CT: 63 
RT: 70 
Both: 92 
EORTC 
QLQ-C30 
1) More deficits in physical function, 
dyspnoea, pain, & fatigue if combined 
modality therapy  
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6. Norum & Wist 
(1996) [27] 
Norway 
1. Document QoL in HLsurvivors  
2. Determine whether mantle field 
irradiation causes reduced QoL 
3. Determine whether QoL differs 
by gender  
HL 42 (86%) 
24 male 
Not reported Not reported RT: 10 
CT: 16 
Both: 16 
EORTC 
QLQ C-30 
1) Mantle field radiation: dyspnoea 
2) Males greater fatigue, lower HRQoL 
3) Sleep disturbance: fatigue, pain, financial 
difficulties, dyspnoea, worse HRQoL 
4) Physical condition/ medical treatment 
caused financial difficulties in 45% 
 
7. Vallance et al. 
(2005)  [28] 
Canada 
1. Examine HRQoL differences 
between NHL survivors meeting 
and not meeting exercise guidelines 
NHL 438 
(62%) 
51.6% male 
61.1 [13.1] 62 [25.3] 
(months) 
CT: 64.6% 
CT+RT: 15.5% 
Wait: 17.1% 
 
 
FACT-An 1) Meeting exercise guidelines (150 
minutes/ week): better physical, emotional 
and functional HRQoL 
8. Zebrack et al. 
(2008) [29] 
USA 
1. Examine relation between 
perceptions of impact of cancer and 
HRQoL, across cancers, after 
controlling for medical and socio-
demographic factors 
193 (33%) 
49 HL/NHL 
56% male 
(overall) 
61.5 
[14.3]Whole 
sample 
7.7 [1.9] Not reported SF-36 
QOL-CS 
1) Fewer co-morbidities: better physical 
health, HRQoL 
2) Younger age: better physical health, but 
worse mental health, overall HRQoL  
3) Employed: better physical health 
 
Glossary: QOL-CS – Quality of Life – Cancer Survivors; CT – chemotherapy; RT – radiotherapy; SF-36 – Short Form 36 health survey; STLI – subtotal lymphoid 
irradiation; CMT – combined modality therapy; CARES-SF – Cancer Rehabilitation Evaluation System – Short Form; EORTC QLQ-C30 : European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire; FACT-An – Functional Assessment of Cancer Therapy – Anaemia 
 
*These studies are drawn from the same population 
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 Figure 1: Search process 
Keyword search generated hits: 
PsycInfo (n=32); Medline (n=157); WoK (n=456) 
36 articles identified as potentially eligible on basis 
of abstract 
Full text obtained for 35 articles 1 untraceable 
Search of reference lists: 9 further articles 
identified  
Full text obtained for 45 articles 
 
Manual search of the journals:  Psycho-Oncology, 
European Journal of Cancer, Journal of Clinical 
Oncology and Quality of Life Research: 1 further 
article identified 
27 papers excluded on basis of complete article  
review 
18 eligible articles retained 
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Figure II: Summary of Findings and Recommendations for Future Research 
 
Measures 
 Measures designed for use during treatment used on long-
term cancer survivors 
 
Recommendation:  
 
 Studies should utilise a survivor-specific and a generic 
measure of HRQoL 
 
Correlates of HRQoL 
 
 Lymphoma survivors have poor physical HRQoL, but mental 
HRQoL equivalent to general population on average 
 Correlates of better physical HRQoL: younger age, higher 
educational level, following exercise guidelines 
 Insufficient evidence to determine:  
1) Effects of treatment on HRQoL 
2) Relation between psychological factors and 
HRQoL 
 
Recommendations for future research: 
 
 Use of longitudinal designs 
 Detailed reporting of demographics and descriptive statistics 
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